1. Impact of a pharmacist-driven recombinant zoster vaccine administration program
- Author
-
Patricia Pecora Fulco and Allison M. Porter
- Subjects
medicine.medical_specialty ,Pharmacist ,Pharmacology (nursing) ,Pharmacy ,Pharmacists ,Herpes Zoster ,030226 pharmacology & pharmacy ,03 medical and health sciences ,0302 clinical medicine ,Intervention (counseling) ,Internal medicine ,Herpes Zoster Vaccine ,Humans ,Medicine ,Pilot program ,030212 general & internal medicine ,Retrospective Studies ,Pharmacology ,Vaccines, Synthetic ,Intention-to-treat analysis ,business.industry ,Retrospective cohort study ,Cohort ,Zoster vaccine ,business ,Administration (government) ,medicine.drug - Abstract
Objective To determine whether a pharmacist-driven recombinant zoster vaccine (RZV) administration pilot program within a human immunodeficiency virus/infectious diseases clinic setting increased the completion of the 2-dose series when compared with standard care. Methods In this retrospective cohort study, the patients enrolled in a pharmacist-driven RZV administration pilot program (intervention) were compared with those in provider-directed RZV education (standard care) for completion of the 2-dose vaccine series. Results One hundred nineteen patients were included (standard care [n = 84], intervention intention to treat [ITT, n = 35], and intervention modified ITT [mITT, n = 23]). There was increased completion of the 2-dose vaccine series in the intervention cohort compared with the standard care cohort (ITT 66% and mITT 100% vs. 23%; P Conclusion The pharmacist-driven RZV administration program resulted in increased completion of the 2-dose series. However, the revenue generated did not justify the cost of a pharmacist salary for the allocated time commitment.
- Published
- 2021
- Full Text
- View/download PDF